Clinical Trial Update: An Open-Label Study Investigating MK-8931 in Participants With Mild and Moderate Hepatic Insufficiency (MK-8931-016) [Phase 1]

View source ↗

Summary

Phase 1 open-label study of MK-8931 in participants with hepatic impairment; results completed with conditions including amnestic mild cognitive impairment and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Amnestic Mild Cognitive Impairment

Drugs mentioned

• MK-8931 (MK-8931)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Amnestic Mild Cognitive Impairment, Alzheimer's Disease | Phase 1 | Status: COMPLETED | Results posted: 2018-10-01